Jasper TherapeuticsJSPR
Market Cap: $360M
About: Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Employees: 45
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
330% more call options, than puts
Call options by funds: $3.19M | Put options by funds: $742K
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
13% more funds holding
Funds holding: 60 [Q1] → 68 (+8) [Q2]
8.84% more ownership
Funds ownership: 87.63% [Q1] → 96.47% (+8.84%) [Q2]
14% less capital invested
Capital invested by funds: $385M [Q1] → $330M (-$55.5M) [Q2]
17% less funds holding in top 10
Funds holding in top 10: 6 [Q1] → 5 (-1) [Q2]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
JMP Securities Silvan Tuerkcan 43% 1-year accuracy 20 / 46 met price target | 194%upside $70 | Market Outperform Initiated | 9 Sept 2024 |
Evercore ISI Group Gavin Clark-Gartner 64% 1-year accuracy 7 / 11 met price target | 173%upside $65 | Outperform Maintained | 26 Aug 2024 |
RBC Capital Gregory Renza 52% 1-year accuracy 34 / 66 met price target | 185%upside $68 | Outperform Maintained | 14 Aug 2024 |
HC Wainwright & Co. Emily Bodnar 31% 1-year accuracy 35 / 112 met price target | 173%upside $65 | Buy Reiterated | 13 Aug 2024 |
HC Wainwright & Co. Emily Bodnar 31% 1-year accuracy 35 / 112 met price target | 173%upside $65 | Buy Reiterated | 5 Aug 2024 |